| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for immunotherapy of cancer 5, 1-28, 2017 | 1684 | 2017 |
| Ipilimumab for patients with relapse after allogeneic transplantation MS Davids, HT Kim, P Bachireddy, C Costello, R Liguori, A Savell, ... New England Journal of Medicine 375 (2), 143-153, 2016 | 569 | 2016 |
| Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer discovery 8 (2), 196-215, 2018 | 433 | 2018 |
| Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients RA Clark, R Watanabe, JE Teague, C Schlapbach, MC Tawa, N Adams, ... Science translational medicine 4 (117), 117ra7-117ra7, 2012 | 379 | 2012 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 328 | 2016 |
| Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the … I Puzanov, A Diab, K Abdallah, CO Bingham 3rd, C Brogdon, R Dadu, ... J immunother Cancer 5 (1), 95, 2017 | 222 | 2017 |
| Dermatological adverse events with taxane chemotherapy V Sibaud, NR Lebœuf, H Roche, VR Belum, L Gladieff, M Deslandres, ... European Journal of Dermatology 26, 427-443, 2016 | 220 | 2016 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... Cancer discovery 7 (2), 156-164, 2017 | 199 | 2017 |
| TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL IR Kirsch, R Watanabe, JT O’Malley, DW Williamson, LL Scott, CP Elco, ... Science translational medicine 7 (308), 308ra158-308ra158, 2015 | 199 | 2015 |
| Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors AC Guidon, LB Burton, BK Chwalisz, J Hillis, TH Schaller, AA Amato, ... Journal for immunotherapy of cancer 9 (7), 2021 | 112 | 2021 |
| High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides A De Masson, JT O’Malley, CP Elco, SS Garcia, SJ Divito, EL Lowry, ... Science translational medicine 10 (440), eaar5894, 2018 | 105 | 2018 |
| Successful Treatment of a Progressive BRAF V600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy EQ Lee, S Ruland, NR LeBoeuf, PY Wen, S Santagata Journal of Clinical Oncology 34 (10), e87-e89, 2016 | 103 | 2016 |
| Rituximab treatment of nivolumab-induced bullous pemphigoid L Sowerby, AK Dewan, S Granter, L Gandhi, NR LeBoeuf JAMA dermatology 153 (6), 603-605, 2017 | 95 | 2017 |
| Cutaneous adverse events caused by immune checkpoint inhibitors HT Quach, DB Johnson, NR LeBoeuf, JP Zwerner, AK Dewan Journal of the American Academy of Dermatology 85 (4), 956-966, 2021 | 81 | 2021 |
| Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 therapy K Tang, J Seo, BC Tiu, TK Le, V Pahalyants, NS Raval, PO Ugwu-Dike, ... JAMA dermatology 158 (2), 189-193, 2022 | 73 | 2022 |
| Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes CA Nelson, S Singer, T Chen, AE Puleo, CG Lian, EX Wei, ... Journal of the American Academy of Dermatology 87 (6), 1400-1402, 2022 | 55 | 2022 |
| Regulatory and safety considerations in deploying a locally fabricated, reusable face shield in a hospital responding to the COVID-19 pandemic A Mostaghimi, MJ Antonini, D Plana, PD Anderson, B Beller, EW Boyer, ... Med 1 (1), 139-151. e4, 2020 | 51 | 2020 |
| Extramammary Paget's disease M Asel, NR LeBoeuf Hematology/Oncology Clinics 33 (1), 73-85, 2019 | 51 | 2019 |
| Update on the management of high-risk squamous cell carcinoma NR LeBoeuf, CD Schmults , 30, 1 30 (1), 26-34, 2011 | 49 | 2011 |
| Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma A Alloo, L Garibyan, N LeBoeuf, G Lin, A Werchniak, FS Hodi, KT Flaherty, ... Archives of dermatology 148 (3), 363-366, 2012 | 48 | 2012 |
